AIM: To study the inhibitory effects of a Shuangling Fuzheng anticancer preparation (SFAP) on the human gastric cancer cell line SGC-7901 in vitro as well as its immune-modulated effects in a cyclophosphamide-treated murine model. METHODS: MTT experiments and immunocytochemistry ABC experiments were performed for detecting the proliferation of SGC-7901 cells in vitro and protein expression of c-myc. The staphylococcal protein A (SPA) rosette test was utilized for measuring the ratio of T-lymphocyte subsets from peripheral blood in a cyclophosphamide-treated murine model. Enzyme-linked immunosorbant assay (ELISA) was performed for measuring the levels of serum sIL-2R in treated mice, while immunoturbidimetry was used for measuring the levels of immunoglobulins (Ig). RESULTS: SFAP (40-640 mg/L, 48 h) inhibited the proliferation of SGC-7901 cells, and a positive correlation was noted between inhibitory effects and dosage. At a dosage of 160-320 mg/L in cultured cells, the expression of c-myc was decreased. SFAP (50-200 mg/kg) increased the percentage of CD3+ and CD4+ T-lymphocytes, the ratio of CD4/CD8, and the contents of Ig such as IgM, IgG or IgA, but decreased the levels of serum sIL-2R in peripheral blood from cyclophosphamide-treated mice. CONCLUSION: SFAP can inhibit the proliferation of SGC-7901 cells via the c-myc gene. In addition, SFAP can modulat the cellular and humoral immunity in cyclophosphamide-induced immunosuppressed mice.
AIM: To study the inhibitory effects of a Shuangling Fuzheng anticancer preparation (SFAP) on the humangastric cancer cell line SGC-7901 in vitro as well as its immune-modulated effects in a cyclophosphamide-treated murine model. METHODS:MTT experiments and immunocytochemistry ABC experiments were performed for detecting the proliferation of SGC-7901 cells in vitro and protein expression of c-myc. The staphylococcal protein A (SPA) rosette test was utilized for measuring the ratio of T-lymphocyte subsets from peripheral blood in a cyclophosphamide-treated murine model. Enzyme-linked immunosorbant assay (ELISA) was performed for measuring the levels of serum sIL-2R in treated mice, while immunoturbidimetry was used for measuring the levels of immunoglobulins (Ig). RESULTS: SFAP (40-640 mg/L, 48 h) inhibited the proliferation of SGC-7901 cells, and a positive correlation was noted between inhibitory effects and dosage. At a dosage of 160-320 mg/L in cultured cells, the expression of c-myc was decreased. SFAP (50-200 mg/kg) increased the percentage of CD3+ and CD4+ T-lymphocytes, the ratio of CD4/CD8, and the contents of Ig such as IgM, IgG or IgA, but decreased the levels of serum sIL-2R in peripheral blood from cyclophosphamide-treated mice. CONCLUSION: SFAP can inhibit the proliferation of SGC-7901 cells via the c-myc gene. In addition, SFAP can modulat the cellular and humoral immunity in cyclophosphamide-induced immunosuppressed mice.
Authors: Sander Zwaveling; Michel P M Vierboom; Sandra C Ferreira Mota; Jennifer A Hendriks; Marlies E Ooms; Roger P M Sutmuller; Kees L M C Franken; Hans W Nijman; Ferry Ossendorp; Sjoerd H Van Der Burg; Rienk Offringa; Cornelis J M Melief Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: H Liu; C R Lo; B E Jones; Z Pradhan; A Srinivasan; K L Valentino; R J Stockert; M J Czaja Journal: J Biol Chem Date: 2000-12-22 Impact factor: 5.157
Authors: Axel C P Diederichsen; J v B Hjelmborg; Per B Christensen; Jesper Zeuthen; Claus Fenger Journal: Cancer Immunol Immunother Date: 2003-04-15 Impact factor: 6.968
Authors: Koen Schepers; Mireille Toebes; Gitte Sotthewes; Florry A Vyth-Dreese; Trees A M Dellemijn; Cornelis J M Melief; Ferry Ossendorp; Ton N M Schumacher Journal: J Immunol Date: 2002-09-15 Impact factor: 5.422
Authors: James C Yao; Paul F Mansfield; Peter W T Pisters; Barry W Feig; Nora A Janjan; Christopher Crane; Jaffer A Ajani Journal: Semin Surg Oncol Date: 2003